The Centre for Drug Research and Development (CDRD) and the Prevention of Organ Failure Centre (PROOF Centre), both inaugural Centres of Excellence for Commercialization and Research (CECRs) headquartered in Vancouver, have entered into a “Preferred Collaboration Agreement” to bring more effective diagnoses and therapies to patients faster.
Through this agreement, PROOF’s expertise in identifying and developing clinically-relevant biomarker solutions for the clinical laboratory and in support of industry, computational resources, repository of plausible drug targets, and molecular signatures of physiological responses and states; will be aligned with CDRD’s expertise in the development of target- and mechanism-based therapeutics. Both organizations are also engaged in different facets of companion diagnostics development.
CDRD president and CEO, Karimah Es Sabar commented on the partnership, “In today’s world of drug development and personalized medicine, diagnostics are a key part of bringing the right novel therapies to the right patients; and we must therefore tailor this development to the optimal benefits of patients.”
PROOF Centre CEO, Bruce McManus noted, “There is an enormous need for blood tests with better performance, higher value, and bigger clinical impact than now available. Similarly, the therapeutic industry needs biosignatures that enhance the speed and quality of decision-making in product development. Our exciting partnership will spur this essential direction.”
Together, the two organizations hope to synergize their development efforts focused on highly-relevant targets and mechanisms; improve methods for assessing mechanism of actions, therapeutic efficacy, and toxicity of candidate therapeutics; and build companion biomarker panels to advance personalized medicine and improve patient outcomes.